# Neoadjuvant Ipilimumab in Prostate Cancer

> **NCT01194271** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Leuprolide Acetate
- **DRUG:** Ipilimumab
- **PROCEDURE:** Radical Prostatectomy

## Key facts

- **NCT ID:** NCT01194271
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01194271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01194271, "Neoadjuvant Ipilimumab in Prostate Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01194271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*